Ablation Study Sample Clauses

Ablation Study. We performed experiments to show how much each component of GAM contributes to its success, as follows:
Sample 1Sample 2Sample 3
Ablation Study. Additionally, we conducted an ablation study to identify the best way of integrating the textual hints into our MCL framework. In addition to our MCL+Text method, we also explored the following strategies for injecting particles:
Sample 1
Ablation Study. In this ablation experiment, we aim to verify the importance of Expert Proxy, Expert-specific loss, Expert Assignment mechanism, and Expert Con- fidence. To verify the importance of these com- ponents, we remove them one at a time to eval- uate their impacts in terms of w-Acc. and w-F1. on the IEMOCAP dataset. The ablation experi- ment results are shown in Table 3. We can see that when each of the above components is removed, the model’s scores on the w-F1. and w-Acc. met- rics are reduced to varying degrees. In particular, the effects on the model’s performance from large to small are Expert Proxy, Expert-specific Loss, Expert Assignment, and Expert Confidence. When the Expert Proxy is removed, EAAN-ERC can- not assign the proxy model to represent the unseen evaluator, which biases the final evaluation results. When Expert-specific Loss is removed, although the models in the expert pool can represent the eval- uators, they cannot learn the evaluation experience of the corresponding evaluators, thus the perfor- xxxxx of the EAAN-ERC decreases when perform- ing evaluator-specific emotional evaluation. When Expert Assignment is removed, all expert models in the expert pool are assigned to participate in emo- tion evaluation, which also brings a certain bias to the final evaluation results. We observe that the Expert Assignment has a relatively small impact on model performance. This may be due to the more comprehensive emotional representation extracted by more expert models, despite being perturbed by irrelevant evaluators, which causes a relatively small reduction in model performance. Finally, when Expert Confidence is removed, the perfor- xxxxx of the model decreases minimally, which means that calculating confidence will strengthen to a certain extent the overall assessment of agree- upon emotions. In summary, through this ablation experiment, we verified how important these com- ponents are to the model performance.
Sample 1
Ablation Study. The conducted ablation study on the CATER-v1 dataset underlines the critical role of the Neural ODE module in our TiV-ODE framework and its resilience against irregular video inputs. By evaluating scenarios with videos of irregular timesteps and replacing the Neural ODE module with a step-wise transition model, we affirm the necessity of our methodological choices. Quantitative results of the ablation study are presented in Table 13. The quantitative outcomes from this study not only reinforce our method's robustness against irregularities in video data but also highlight the Neural ODE module's effectiveness in enhancing our model's video generation capabilities, distinguishing our approach from prior works. Table 13: TiV-ODE Ablation Study on CATER-v1 Dataset TiV-ODE 0.96 11.98 0.12 TiV-ODE - with irregular timesteps 0.96 13.71 0.13 TiV-ODE - without ODE solver 0.90 31.56 0.28
Sample 1
Ablation Study. We carried out an ablation study on two high-precision tasks: peg insertion and kits assembling, to evaluate the contribution of the Dynamic-NODE to NODE-IL's effectiveness and to assess NODE-IL's robustness. The study involved two experimental conditions: (i) removing the Dynamic-NODE, allowing the Control-NODE to interact directly with the simulation environment, and (ii) introducing random Gaussian noise X∼N(0,σ^2) to the state observations from the simulation during the testing phase, with experiments conducted across noise levels σ=[0.1,0.2,0.3,0.4,0.5]. The results detailed in Table 17 and Figure 20 reveal that omitting the Dynamic-NODE and directly engaging the Control-NODE with the simulation decreases performance by 5.5%, highlighting the Dynamic-NODE's significant role in NODE-IL's overall efficacy. Furthermore, the NODE-IL framework exhibited resilience to random noise, maintaining robust control policies at noise levels up to σ=0.
Sample 1
Ablation Study. The ablation study results are depicted in the Figure 25, showing reference trajectories (dashed-black lines), closed-loop (solid-red lines), and open-loop (solid-blue lines) actual trajectories. This visual representation illustrates each model's capability in tracking trajectories under different conditions. Table 20 summarizes the trajectory tracking results in both open-loop and closed-loop configurations for seen and unseen scenarios. It provides the root mean squared error (RMSE) and standard deviation (σ) for each model, highlighting the ANODE model's superior performance. Table 20: Ablation and comparison results of trajectory tracking scenarios; -O/-C tokens refer to open-loop and closed-loop results, respectively. Scenario Model RMSE x(mm) RMSE y(mm) RMSE z(mm) σ x(mm) σ y(mm) σ z(mm) Seen-Closed (C) MLP 0.531 0.548 0.570 0.531 0.548 0.869 Seen-Open (O) MLP 0.572 0.563 0.702 0.557 0.543 0.494 Seen-C RNN 0.542 0.537 5.100 0.541 0.537 0.498 Seen-O RNN 0.576 0.546 5.000 0.544 0.540 0.419 Seen-C ANODE 0.105 0.127 0.116 0.105 0.127 0.116 Seen-O ANODE 0.198 0.177 0.122 0.198 0.177 0.121 Unseen-C/O MLP/RNN - - - - - - Unseen-C ANODE 0.256 0.164 0.157 0.256 0.164 0.157 Unseen-O ANODE 5.600 3.100 4.900 4.700 1.800 2.900 This section introduced a new method for modelling the continuous forward kinematic models of soft continuum robots using ANODE. The proposed method only required 25 scattered data points. Additionally, we developed a parallel MPPI-based controller running on a GPU, which effectively handles a non-convex objective function. This design enhances the adaptability and robustness of the learned model, enabling accurate prediction and control of soft continuum robot motion in various new scenarios. Through extensive experimentation, ablation, and comparison studies, our proposed framework (ANODE+MPPI) exhibits superior performance over learning-based approaches like FNN and RNN in unseen-before scenarios. It also slightly outperforms them in seen-before settings. Online Estimation of Articulated Objects with Factor Graphs using Vision and Proprioception
Sample 1
Ablation Study. An ablation study was conducted to validate the effectiveness of the proposed network design. We tested variations of our model on the OCID-Grasp dataset: one without predicting the object class label and another without generating the instance mask.
Sample 1
Ablation Study. To justify our use of both low-level and hierarchical xxxxx- tic information, we conducted an ablation study. We analyzed three strategies for integrating semantic knowledge into an MCL framework. SMCL uses only semantic cues through the semantic visibility model. HMCL uses semantic hierar- chy, described in Sec. III-G, to initialize the particles only in the rooms corresponding to the observed room category, and then relies solely on the LiDAR information. HSMCL combines both strategies. The ATE was computed only on stable sequences with 100% success rate. As can be seen in Tab. VI, utilizing the two levels of semantic information benefits localization. HSMCL was able to localize stably even on the challenging sequences, where other methods failed. The ATE for HSMCL is on par with the other methods, and Method Hierarchy Semantics Success ATE ATE (# of stable sequences) (# of successful runs) MCL 27% - (0) 0.046/0.20 (15) HMCL C 61% 0.046/0.21 (3) 0.044/0.19 (34) SMCL C 81% 0.055/0.23 (7) 0.066/0.24 (45) HSMCL C C 100% 0.079/0.23 (11) 0.079/0.23 (55) TABLE VII: Runtime for HSMCL, with 10,000 particles. The Yolov5s results are for inference on a single camera. Platform Sem. Visibility Beam-End Yolov5s (640x480) Yolov5s (320x240) NUC10i7FNK 55 ms 24 ms 223 ms 57 ms Dell Precision-3640-Tower 19 ms 14 ms 10 ms 6.8 ms the slightly larger error can be attributed to including more challenging sequences and runs in the computation of the ATE for HSMCL, sequences and runs where other methods failed to localize entirely.
Sample 1

Related to Ablation Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.